EGFR and colorectal carcinoma: Experiments on xenografts derived from patients not exposed to anti-EGFR moAbs showed that treatment with cetuximab was not effective in mice engrafted with CRC specimens carrying MET amplification, suggesting that MET amplification may be involved in primary resistance [64].